Medical microbiology

ATLAS OCEAN VOYAGES INTRODUCES NEW CULTURAL EXPEDITION PROGRAMMING FOR 2024

Retrieved on: 
Thursday, March 7, 2024
Museum, Social work, Royal Horticultural Society, Architecture, Doctor of Philosophy, Royal, Culture, Medical microbiology, Scott Polar Research Institute, University, RSPB, Religious broadcasting, Victoria and Albert Museum, Fossil, Local government, Atlas, British Museum, Fellow, Plant, University of Leicester, MBA, Radio, Gardening, BBC, Economics, Disabled parking permit, Environmental science, Education, Pepperdine University, FPV, Pritikin diet, Life, American Red Cross, Physics, Exploration, Research, Collection, Politics, Royal Society, University of Cambridge, Radio 4, Arawak, Emeritus, Imperial College London, Carib, WSI, Geological Society of London, UC, Emmanuel College, RHS, Tourism

FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season. An addition to the company's year-round expeditions that include Polar and Epicurean Expeditions, these new programs enhance appreciation for a variety of captivating regions and local cultures.

Key Points: 
  • FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season.
  • Atlas Ocean Voyages Cultural Expeditions include onboard and onshore programming focused on drone and photo workshops, cooking culture, and destination experts.
  • Below is an overview for 2024:
    Guests will embark on an exhilarating journey exclusively with Atlas Ocean Voyages Cultural Expeditions' new Atlas Focus Lab: Drone & Photo Workshops.
  • Combining an intimate and luxurious environment with genuine hospitality, Atlas Ocean Voyages ensures that each journey is a once-in-a-lifetime expedition.

Copan Colibrí™ Receives Third FDA Clearance, Further Expanding Automated ID/AST Workup Capabilities

Retrieved on: 
Tuesday, January 30, 2024
Medical microbiology, Artificial intelligence, Patient, Partnership, The central science, Workflow, Sensitivity and specificity, Microbiology, Beckman Coulter, Laboratory, FDA, Vision system, Use, Medical device

The automated ID/AST preparation instrument is a key component in Copan's full laboratory automation line that revolutionizes the workflow and efficiency of microbiology labs.

Key Points: 
  • The automated ID/AST preparation instrument is a key component in Copan's full laboratory automation line that revolutionizes the workflow and efficiency of microbiology labs.
  • The Colibrí™ system is a fully automated specimen preparation platform designed to prepare MALDI-TOF ID targets and create bacterial suspensions for Antibiotic Susceptibility Testing (AST).
  • The latest FDA clearance recognizes the ability of the Colibrí™ instrument to seamlessly integrate with the Beckman Coulter MicroScan Walkaway Instruments & Panels for ID/AST.
  • Later that year the Colibri™ system received FDA 510(k) clearance for use with bioMérieux VITEK® 2 Antimicrobial Susceptibility Testing System.

Global Point of Care Testing (POCT) Market Report 2023-2030: Continued Expansion of Point of Care Including Self Testing Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024
Nursing, Medical Supplies, Health, Hospitals, General Health, Biotechnology, Diabetes, Medical microbiology, LFA, Infection, Mortality, Conditional sentence, Patient, Mode, Incidence, Diagnosis, Developed country, Clinic, Cancer, Government, Workplace, International Diabetes Federation, Point-of-care testing, Prevalence, POC, Nature, POCT, Physician, Growth, Medical device

The "Global Point of Care Testing Market (By Diagnostics Segment, Mode, End Users, Regions), 100 Company Profiles" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Point of Care Testing Market (By Diagnostics Segment, Mode, End Users, Regions), 100 Company Profiles" report has been added to ResearchAndMarkets.com's offering.
  • Hence, the growing infectious diseases and chronic conditions will drive the point of care testing market over the forecast period.
  • Based on diagnostics segment, the point of care testing market is dominated by blood glucose testing segment.
  • The point of care testing market for immunoassays technology is expected to witness significant growth over the forecast timeframe.

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Retrieved on: 
Monday, January 8, 2024
AMAG Pharmaceuticals, Vaccine, Hospital, Immunoglobulin A, Nephrology, Amgen, Biotechnology, AstraZeneca, Drug development, Allergy, IgA nephropathy, MAA, MedImmune, Darbepoetin alfa, Johns Hopkins University, NDA, Medical microbiology, California State University, Therapy, GSK, Stanford University Medical Center, Peanut allergy, Regulatory affairs, Kidney, SVP, Patient, Hematology, Iron(II,III) oxide, Pharmaceutical industry

The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.

Key Points: 
  • The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.
  • ; and William D. Turner as Chief Development Officer, effective immediately.
  • Rob and Bill each have successfully guided multiple therapies through late clinical development, regulatory approval and commercial launch.
  • This is a key moment for Vera as we continue to advance the strategy for our late-stage clinical program,” said Marshall Fordyce, M.D., Chief Executive Officer of Vera Therapeutics.

bioMérieux Canada, AMMI Canada, EPIC and AMR-One Health Consortium co-host the second Canadian symposium to fight antimicrobial resistance

Retrieved on: 
Wednesday, November 22, 2023
Ministry, EPIC, Global health, Research, Emerging, Microbiology, WHO, OHC, Risk, Disease, One Health, MaRS Discovery District, Infection, Death, Pharmacology, AMR, Diagnosis, Software, Medical microbiology, Veterinary medicine, Physician, Legislation, Public, Education, Ministry of Health, Medical device, Pharmaceutical industry, Health

This scientific summit aims to identify concrete actions to combat antimicrobial resistance while highlighting Canadian research and leadership in this crucial fight.

Key Points: 
  • This scientific summit aims to identify concrete actions to combat antimicrobial resistance while highlighting Canadian research and leadership in this crucial fight.
  • "Infectious Diseases physicians, medical microbiologists and clinical microbiologists are actively involved in research, innovation and education to combat antimicrobial resistance.
  • A One Health approach in line with the Pan-Canadian Action Plan to combat AMR is a priority"," says Dr. Deborah Yamamura, President of AMMI Canada.
  • Several discussions will also focus on the One Health approach, which, with its collaborative cross-disciplinary and cross-sector approach, is essential in the fight against antimicrobial resistance.

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

Retrieved on: 
Tuesday, September 19, 2023
Staphylococcus, MIC, CLSI, Clinical trial, Medical microbiology, Staphylococcus aureus, Patient, Antimicrobial resistance, Clinical and Laboratory Standards Institute, Drug development, Challenge, Campaign, AST, Laboratory, Conference, Clinical, Knee, Peptide, Sosa, Pharmaceutical industry

Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.

Key Points: 
  • Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.
  • She will highlight and discuss various antibiotics in current use and several investigational agents that require a modified AST method, such as the Company’s DLAs.
  • Review and approval of new AST methods by standards development organizations, such as the Clinical and Laboratory Standards Institute (CLSI), is essential.
  • The Company will be presenting two posters describing the initial development of the exebacase MIC method for testing Staphylococci other than Staphylococcus aureus (SoSA) and method verification studies performed to evaluate test performance.

Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

Retrieved on: 
Monday, September 11, 2023
Department of Medical Microbiology (Schering AG), Abstract, Pelvic inflammatory disease, Bachelor of Science, University, Apotex, Medical microbiology, HIV, Cangene, HIV-1, Head, Monoclonal antibody, Public Health Agency of Canada, COVID-19, Woman, CIHR, Infection, Research, Lehigh University, American Biological Safety Association, National Microbiology Laboratory, University of Manitoba, Government, Immunochemistry, Chlamydia trachomatis, Philosophy, Outline, Gynaecology, Blood, Scripps Research, Protein engineering, R, Public Health Agency, G.H. Raisoni Department of Microbiology and Biotechnology, University Arena (Western Michigan University), Vaccine, Science, Chlamydia, Molecular biology, Aspira

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
  • Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
  • Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.

SpotSee Forms Life Science Advisory Council with Global Industry Leaders

Retrieved on: 
Tuesday, June 27, 2023
Software, Health, Packaging, Health Technology, Technology, Logistics, Supply Chain Management, Transport, Manufacturing, Clinical chemistry, GS1, HDA, McRoberts, Abbott, BD (company), Biopharma LLC, Doctor of Philosophy, Medical microbiology, PACT, Organization, IEEE, SITM, Thermo Fisher Scientific, National academy, CPHD, Capital, Stuart, MEMS, IVD, SAP, Growth, Johnson & Johnson, Cathcart, GTT, FDA, Management, Pharmaceutical industry, Pharma, Engineering, Qualcomm, Cepheid variable

SpotSee® , a global leader in supply chain indicators that protect products against damage and ensure supply chain integrity, has assembled its inaugural Life Science Advisory Council, bringing together a team of globally recognized experts.

Key Points: 
  • SpotSee® , a global leader in supply chain indicators that protect products against damage and ensure supply chain integrity, has assembled its inaugural Life Science Advisory Council, bringing together a team of globally recognized experts.
  • SpotSee's Life Science Advisory Council aims to utilize the combined expertise of its members to shape the company's product development, regulatory, and business strategies, thereby bolstering its industry success.
  • SpotSee will take advantage of the group's technical acumen, product development and innovation experience, as well as their industry networks, to accelerate growth in Life Sciences.
  • "We look forward to making SpotSee the premier provider of condition-monitoring solutions for organizations within the life science sector with the help of these carefully selected individuals."

Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends

Retrieved on: 
Friday, March 3, 2023
Research, European, Mater Group, NEXT Woman of the Year awards, Royal college, Australasian, University of the Philippines Manila, Consultant, Senior, Editor-in-chief, Toxicology, IND, Protein, University, Royal Australasian College, Infection, COVID-19, ChromeOS, Marie Cassidy, Associate, Acquisition, Tropical medicine, Principal, Vaccine, Clinical trial, IVI, Drug development, Pharmacist, International Vaccine Institute, Licensure, SOP, Drug Development and Industrial Pharmacy, Medical microbiology, SK, Babaji, Pharmaceutical industry, Fine chemical, Pharmacology, Physician, Medicine

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

Artilysin®: Promising Approach Against Acinetobacter baumannii Infected Wounds

Retrieved on: 
Wednesday, March 1, 2023
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical Devices, Hospitals, United Nations, Infection, United, Goethe University Frankfurt, Fungal infection, Federal Ministry of Education and Research (Germany), Acinetobacter baumannii, Teaching hospital, Patient, Education, Federal Ministry of Health (Germany), BMBF, Medical microbiology, Bacteria, Vaccine, Antibiotics, Trauma, Hand

Volkhard A. J. Kempf, Director of the Institute for Medical Microbiology and Hospital Hygiene at University Hospital of Goethe University Frankfurt.

Key Points: 
  • Volkhard A. J. Kempf, Director of the Institute for Medical Microbiology and Hospital Hygiene at University Hospital of Goethe University Frankfurt.
  • Acinetobacter baumannii is one of these pathogens.
  • As bacteria are also always present in neighboring and often non-removable tissue, an innovative approach of local treatment with Artilysin® is a promising future strategy", explains Univ.-Prof. Dr. med.
  • These results provide a promising basis for new therapeutic approaches in the fight against these problematic pathogens.